Are migraineurs at increased risk of adverse drug responses?: A meta-analytic comparison of topiramate-related adverse drug reactions in epilepsy and migraine

Clinical Pharmacology and Therapeutics

Volumn 85, Issue 3, 2009, Pages 283-288

  Luykx, J ^a,b   Mason, M ^c,d   Ferrari, M D ^e   Carpay, J ^f  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^f Tergooi Hospitals   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

PLACEBO; TOPIRAMATE;

ABDOMINAL PAIN; ALOPECIA; ANOREXIA; APPETITE; ARTICLE; CLINICAL TRIAL; CONFUSION; CONSTIPATION; CONTROLLED CLINICAL TRIAL; DEPRESSION; DIARRHEA; DOSE RESPONSE; DRUG MONITORING; DRUG RESPONSE; DYSPHASIA; EPILEPSY; FATIGUE; GASTROINTESTINAL SYMPTOM; HEADACHE; HUMAN; HYPESTHESIA; INSOMNIA; MEMORY DISORDER; MENTAL CONCENTRATION; META ANALYSIS; MIGRAINE; NAUSEA; NERVOUSNESS; PARESTHESIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RASH; RISK ASSESSMENT; SIDE EFFECT; SOMNOLENCE; SYSTEMATIC REVIEW; TASTE DISORDER; TREMOR; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION; WEIGHT GAIN; WEIGHT REDUCTION;

DRUG TOXICITY; EPILEPSY; FRUCTOSE; HUMANS; MIGRAINE DISORDERS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK FACTORS;

EID: 60349086313     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/clpt.2008.203     Document Type: Article

References (24)

1. Bigal, M.E., Lipton, R.B., Cohen, J. & Silberstein, S.D. Epilepsy and migraine. Epilepsy Behav. 4(suppl. 2),13-24 (2003).
2. Chen, S.C. Epilepsy and migraine: the dopamine hypotheses. Med. Hypotheses 66, 466-472 (2006).
3. Kullmann, D.M. & Hanna, M.G. Neurological disorders caused by inherited ion-channel mutations. Lancet Neurol. 1, 157-166 (2002).
4. Brandes, J.L. et al. Topiramate for migraine prevention: a randomized controlled trial. JAMA 291, 965-973 (2004).
5. Diener, H.C. et al. Topiramate in migraine prophylaxis - results from a placebo-controlled trial with propranolol as an active control. J. Neurol. 251, 943-950 (2004).
6. Mei, D.A. et al. Topiramate in migraine prophylaxis: a randomised double-blind versus placebo study. Neurol. Sci. 25, 245-250 (2004).
7. Silberstein, S.D. et al. Efficacy and tolerability of topiramate 200 mg/d in the prevention of migraine with/without aura in adults: a randomized, placebo-controlled, double-blind, 12-week pilot study. Clin. Ther. 28, 1002-1011 (2006).
8. Silberstein, S.D., Neto, W., Schmitt, J. & Jacobs, D. MIGR-001 Study Group. Topiramate in migraine prevention: results of a large controlled trial. Arch. Neurol. 61, 490-495 (2004).
9. Silvestrini, M., Bartolini, M., Coccia, M., Baruffaldi, R., Taffi, R. & Provinciali, L. Topiramate in the treatment of chronic migraine. Cephalalgia 23, 820-824 (2003).
10. Arroyo, S. et al. Randomized dose-controlled study of topiramate as first-line therapy in epilepsy. Acta Neurol. Scand. 112, 214-222 (2005).
11. Gilliam, F.G. et al. A dose-comparison trial of topiramate as monotherapy in recently diagnosed partial epilepsy. Neurology 60, 196-202 (2003).
12. Privitera, M.D. et al. Topiramate, carbamazepine and valproate monotherapy: double-blind comparison in newly diagnosed epilepsy. Acta Neurol. Scand. 107, 165-175 (2003).
13. Sachdeo, R.C., Reife, R.A., Lim, P. & Pledger, G. Topiramate monotherapy for partial onset seizures. Epilepsia 38, 294-300 (1997).
14. McDowell, M.A., Fryar, C.D., Hirsch, R. & Ogden, C.L. Anthropometric reference data for children and adults: U.S. population, 1999-2002. Adv. Data 361, 1-5 (2005).
15. Johnson, B.A. et al. Topiramate for treating alcohol dependence: a randomized controlled trial. JAMA 298, 1641-1651 (2007).
16. Albsoul-Younes, A.M., Salem, H.A., Ajlouni, S.F. & Al-Safi, S.A. Topiramate slow dose titration: improved efficacy and tolerability. Pediatr. Neurol. 31, 349-352 (2004).
17. Korian Topiramate Study Group. Low dose and slow titration of topiramate as adjunctive therapy in refractory partial epilepsies: a multicentre open clinical trial. Seizure 11, 255-260 (2002).
18. Ferrari, M.D., Roon, K.I., Lipton, R.B. & Goadsby, P.J. Oral triptans (serotonin 5-HT (1B/1D) agonists) in acute migraine treatment: a meta-analysis of 53 trials. Lancet 358, 1668-1675 (2001).
19. Loke, Y.K. & Derry, S. Reporting of adverse drug reactions in randomised controlled trials - a systematic survey. BMC Clin. Pharmacol. 1, 3 (2001).
20. Ioannidis, J.P. & Lau, J. Completeness of safety reporting in randomized trials: an evaluation of 7 medical areas. JAMA 285, 437-443 (2001).
21. Derry, S., Kong Loke, Y. & Aronson, J.K. Incomplete evidence: the inadequacy of databases in tracing published adverse drug reactions in clinical trials. BMC Med. Res. Methodol. 1, 7 (2001).
22. Burstein, R., Yarnitsky, D., Goor-Aryeh, I., Ransil, B.J. & Bajwa, Z.H. An association between migraine and cutaneous allodynia. Ann. Neurol. 47, 614-624 (2000).
23. Goadsby, P.J. et al. Treatment-emergent CNS symptoms following triptan therapy are part of the attack. Cephalalgia 27, 254-262 (2007).
24. Peeters, G.G., Verhagen, A.P., de Bie, R.A. & Oostendorp, R.A. The efficacy of conservative treatment in patients with whiplash injury: a systematic review of clinical trials. Spine 26, E64-E73 (2001).